Site Editor
Jeremy S. Abramson, MD, MMSc
Jeremy S. Abramson, MD, MMSc
Posted: Thursday, February 6, 2025
For patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), management with a single dose of the chimeric antigen receptor (CAR) T-cell immunotherapy lisocabtagene maraleucel remains an effective treatment strategy, resulting in sustained clinical outcomes, according to an update from the TRANSCEND CLL 004 study presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 4633). No new treatment-related safety concerns were reported, making lisocabtagene maraleucel a favorable therapeutic option, according to Tanya Siddiqi, MD, MBBS, of City of Hope National Medical Center, Duarte, California, and colleagues.
A total of 137 patients with relapsed or refractory CLL or SLL were recruited for the study. All patients were treated with at least two previous therapies including a Bruton’s tyrosine kinase inhibitor. After completing lymphodepleting chemotherapy, patients were randomly assigned to receive treatment with lisocabtagene maraleucel at a dose of either 50 × 106 (dose level [DL] 1) or 100 × 106 (DL2). Subset analyses were also performed in patients who failed to respond to venetoclax therapy and patients who were venetoclax-naive.
The study authors reported that patients treated with DL2 in the primary efficacy analysis set analysis had either a complete response or a complete response with incomplete marrow recovery of 20%. In this group of patients, the overall response rate, blood-undetectable measurable residual disease (MRD) rate, and marrow-undectectable MRD rate were 44%, 64%, and 60%, respectively. Moreover, the median duration of response was not reached in these patients. In venetoclax-naive patients treated with DL2, the complete response or complete response with an incomplete marrow recovery rate and overall response rate were 22% and 61%, respectively. Furthermore, the extent of treatment-related adverse events reported by patients remained similar to previously cited rates.
Disclosure: For full disclosures of the study authors, visit ash.confex.com.
2024 ASH Annual Meeting & Exposition
